Company intelligence / Profile preview

IonMed

Yokneam Illit, Tel Aviv District, Israelionmed.us ↗

Ownership: Private
Development stage: Commercial

Overview

IonMed developed and commercialized BioWeld1™, a non-invasive plasma-based system for sutureless surgical incision closure and tissue repair. The device received CE marking in Europe and was used clinically for improved wound healing outcomes compared to traditional sutures or staples. No recent clinical trial updates are available from the provided sources or public domain.

Therapeutic areas: OtherDermatology
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Bioweld1

Commercial

Indications: Surgical wound closure

Beyond the preview

Go deeper on IonMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IonMed.

Explore the full profile